Cargando…

May interferon λ be a novel therapeutic approach against COVID-19?

Detalles Bibliográficos
Autores principales:	Roohi, Azam, Soroosh, Pejman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581317/ https://www.ncbi.nlm.nih.gov/pubmed/33129578 http://dx.doi.org/10.1016/j.mehy.2020.110351

Ejemplares similares

Interferon-λ Genetic Variations and Hepatitis C: Yet to be Discovered
por: Keshvari, Maryam, et al.
Publicado: (2014)

Beta-thalassemia may protect against COVID 19
por: Drouin, Emmanuel
Publicado: (2020)

Interferon-λ at the Center of the Storm
por: Hendricks, Matthew R., et al.
Publicado: (2020)

Comment on: “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”
por: Zhang, Song, et al.
Publicado: (2021)

Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications
por: Hermant, Pascale, et al.
Publicado: (2014)

Interferon-λ in HCV Infection and Therapy
por: Pagliaccetti, Nicole E., et al.
Publicado: (2010)

An incentive-based approach may be the only approach to achieve COVID-19 herd immunity
por: Fradkin, C.
Publicado: (2021)

Reply to Zhang and Zhu “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”
por: Ahmed, Nadine, et al.
Publicado: (2021)

Crystal Structure of Human Interferon-λ1 in Complex with Its High-Affinity Receptor Interferon-λR1
por: Miknis, Zachary J., et al.
Publicado: (2010)

The Unresolved Role of Interferon-λ in Asthma Bronchiale
por: Sopel, Nina, et al.
Publicado: (2017)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020)

COVID-19 and anticoagulant based therapeutics: Approach with great promise
por: Sharma, Varun Kumar, et al.
Publicado: (2021)

An unusual case of necrobiotic xanthogranuloma with IgG-λ monoclonal gammopathy presenting as cerebral manifestations
por: Li, Yiman, et al.
Publicado: (2023)

May polyenthesitis follow COVID-19?
por: Ciaffi, Jacopo, et al.
Publicado: (2021)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese
por: Chen, Ji-Yih, et al.
Publicado: (2018)

Liver injury in COVID-19 – The culprit may not be COVID-19!
por: Singh, Aditya, et al.
Publicado: (2021)

Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
por: Bennani, N.N., et al.
Publicado: (2020)

Comment on “Colchicine may not be effective in COVID-19 infection; it may even be harmful?”
por: Kobak, Senol
Publicado: (2020)

Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
por: Lazear, Helen M., et al.
Publicado: (2015)

Editorial: Interferon-λs: New Regulators of Inflammatory Processes
por: Zanoni, Ivan, et al.
Publicado: (2019)

COVID-19 exposure and obstructive sleep apnea: a therapeutic approach
por: Mohit, et al.
Publicado: (2021)

Patients with interferon expressing oral pathologies are susceptible to COVID-19 infection
por: Sarode, Gargi S., et al.
Publicado: (2020)

Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19
por: Yang, Alexander, et al.
Publicado: (2020)

Reply to Jakovac: COVID-19, vitamin D, and type I interferon
por: Gauzzi, Maria Cristina, et al.
Publicado: (2020)

Recovery from Covid-19 may be prolonged
por: Gupta, Harish, et al.
Publicado: (2021)

1346. Genetic Variation at the Interferon λ Locus and Association with Clinical Outcome and Severity of COVID-19
por: Alalwan, Dana, et al.
Publicado: (2023)

Interferon-λ Contributes to Innate Immunity of Mice against Influenza A Virus but Not against Hepatotropic Viruses
por: Mordstein, Markus, et al.
Publicado: (2008)

Wearing masks and the fight against the novel coronavirus (COVID-19)
por: Alizargar, Javad
Publicado: (2021)

Complement activation in patients with COVID-19: A novel therapeutic target
por: Cugno, Massimo, et al.
Publicado: (2020)

Use of Tociluzumab in the Thrombocytopenic COVID-19 Patient: A Challenge in the Therapeutic Approach
por: Kuscu, Ozlem Ozkan, et al.
Publicado: (2022)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Genetic factors may affect the severity of COVID-19
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Iron chelation may harm patients with COVID-19
por: Garrick, Michael D., et al.
Publicado: (2020)

Antibiotic consumption may be linked to exaggeration of COVID-19
por: Asaduzzaman, Muhammad, et al.
Publicado: (2020)

Interferon-λ3 Promotes Epithelial Defense and Barrier Function Against Cryptosporidium parvum Infection
por: Ferguson, Sylvia H., et al.
Publicado: (2019)

Nasal commensal Staphylococcus epidermidis enhances interferon-λ-dependent immunity against influenza virus
por: Kim, Hyun Jik, et al.
Publicado: (2019)

Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm
por: González-Nicolás, María Ángeles, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i5jr6jf3i0ff12m4bu9o5aegvd